APR-246 + azacitidine + Azacitidine
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout APR-246 + azacitidine + Azacitidine
APR-246 + azacitidine + Azacitidine is a phase 3 stage product being developed by Aprea Therapeutics for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT03745716. Target conditions include MDS.
What happened to similar drugs?
0 of 4 similar drugs in MDS were approved
Approved (0) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03745716 | Phase 3 | Completed |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 32 |
| KRN321 | Kyowa Kirin | Phase 2 | 35 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 29 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 44 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 36 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 21 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 29 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 27 |
| Panobinostat | Novartis | Phase 2 | 27 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 27 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 28 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 29 |
| Panobinostat | Novartis | Phase 1 | 29 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 27 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 27 |
| Placebo + Romiplostim | Amgen | Phase 2 | 35 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 40 |